Manages manifestations of psychotic disorders. ANDA 215848, held by TWi Pharmaceuticals. Fluphenazine Hydrochloride.
As of Nov 19, 2026, ANDA 215848 (Fluphenazine Hydrochloride), held by TWi Pharmaceuticals, was first approved by FDA on Apr 1, 2022, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Fluphenazine hydrochloride tablets are indicated in the management of manifestations of psychotic disorders. Fluphenazine hydrochloride has not been shown effective in the management of behavioral complications in patients with mental retardation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 1, 2022 | Original application | Approved | None posted |
| Fluphenazine Hydrochloride2.5MG · tablet;oral | Fluphenazine Hydrochloride | Discontinued |
| Fluphenazine Hydrochloride5MG · tablet;oral | Fluphenazine Hydrochloride | Discontinued |
| Fluphenazine Hydrochloride10MG · tablet;oral | Fluphenazine Hydrochloride | Discontinued |
| Fluphenazine Hydrochloride1MG · tablet;oral | Fluphenazine Hydrochloride | Discontinued |
| Jan 22, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 1, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters